GGI
CLDX icon

GordonMD Global Investments’s Celldex Therapeutics CLDX Stock Holding History

GordonMD Global Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
279,720
+109,413
+64% +$3.53M 5.04% 7
2026
Q1 		$5.4M Hold
170,307
– – 3.76% 11
2025
Q4 		$4.63M Buy
+170,307
New +$4.49M 3.32% 13

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GordonMD Global Investments's CLDX Position: Q2 2026 in Review

GordonMD Global Investments increased its Celldex Therapeutics (CLDX) stake by 64% in Q2 2026, buying an estimated $3.53M and bringing the position to 279,720 shares worth $10.4M. The position accounts for 5.04% of the portfolio, ranked #7.

GordonMD Global Investments first reported a position in CLDX in Q4 2025 and has held it in 3 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • GordonMD Global Investments held 279,720 shares of Celldex Therapeutics worth $10.4M as of Q2 2026.
  • GordonMD Global Investments bought 109,413 Celldex Therapeutics shares in Q2 2026, an estimated $3.53M.
  • Celldex Therapeutics made up 5.04% of GordonMD Global Investments's portfolio in Q2 2026, its #7 holding.
  • GordonMD Global Investments first reported a position in Celldex Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on GordonMD Global Investments's 13F filing for Q2 2026, filed 14 Aug 2026.